Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model
2008

Targeting PDGF Signaling in Cervical Cancer

publication Evidence: moderate

Author Information

Author(s): Rakesh K Jain, Johanna Lahdenranta, Dai Fukumura

Primary Institution: Massachusetts General Hospital and Harvard Medical School

Hypothesis

Can targeting PDGF signaling in carcinoma-associated fibroblasts slow the progression of cervical cancer?

Conclusion

Targeting PDGF signaling in carcinoma-associated fibroblasts can slow cervical cancer progression and impair invasive growth.

Supporting Evidence

  • Targeting PDGF signaling can impair the growth of invasive carcinomas.
  • Blocking PDGF receptors in carcinoma-associated fibroblasts can reduce pro-angiogenic factors.
  • Imatinib, a drug that targets PDGF signaling, is suggested for clinical testing in cervical cancer.

Takeaway

This study shows that a specific signaling pathway in cancer cells can be blocked to help slow down cervical cancer growth.

Methodology

The study used a mouse model of cervical carcinogenesis to investigate the effects of blocking PDGF receptors in carcinoma-associated fibroblasts.

Potential Biases

Potential conflicts of interest due to funding and consulting relationships of the authors.

Limitations

The study does not address the potential adverse effects of targeting PDGF signaling on normal tissues and the variability of fibroblast phenotypes across different organs.

Participant Demographics

Mouse model used; no human participants.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0050024

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication